Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|September 1, 2002
- Volume 0 0
Knee Surgery May Not Be Helpful
Advertisement
New findings show that arthroscopic lavage or debridement did not improve outcomes in patients with osteoarthritis of the knee, as reported in the New England Journal of Medicine. A total of 180 patients were randomized to arthroscopic debridement, arthroscopic lavage, or placebo surgery. Neither debridement nor lavage was linked to less pain or better function at 1 year or 2 years, compared with placebo surgery.
Articles in this issue
about 24 years ago
Seperate Powders??about 24 years ago
Pure testosterone isocaproate powder...about 24 years ago
Delivery of progesterone...about 24 years ago
Try a Little Exerciseabout 24 years ago
Seasonal Affective Disorderabout 24 years ago
Most Asthmatics Are Not Using Anti-inflammatory Drugsabout 24 years ago
New Guidelines on Inhaler Packaging Are Issuedabout 24 years ago
Big Babies Have Reduced Diabetes Riskabout 24 years ago
Niacin Therapyabout 24 years ago
Whole-Grain HealthAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5